California Allocates $53 Million for Anti-Bird Flu Medication



The federal government will partially subsidize the cost of the antivirals purchased by states. To date, California to date is one of only 13 states to order the medications, which will be partially subsidized by the Federal Government.

"Through a combination of state purchases and federal stockpiling, California will have access to enough antivirals to treat 25% of California's population — the number of people anticipated to become infected in a pandemic," said Betsey Lyman, deputy director of Public Health Emergency Preparedness for the California Department of Health Services.

According to state health officials, California will spend $53 million to procure 3.7 million courses at the 25% federal discount. A course is the number of doses needed to treat one person. It has also purchased another 68,000 courses at the full price of $1.5 million.

The total will ensure that 10% of Californians have access to antivirals. The state is also entitled to more than 5 million courses in the national stockpile, paid for by the federal government. Combined, the state will have enough antivirals to treat roughly 25% of its population during a pandemic.

Some healthcare professions disagree with California's approach, arguing that an antiviral created today would work in the future. Some states turned down Washington's discounted antivirals because of fears that the virus would mutate, making today's treatments ineffective. Arizona and Colorado are two states that didn't invest in the antivirals offered by the government for fear that they may not work.

The antivirals used to treat the symptoms of influenza include Tamiflu and Relenza, although government stockpiles will contain mostly Tamiflu. Both medications reduce influenza symptoms and lower the risk of transmission. But there is no vaccine that protects humans against the bird flu virus. The changeability of the virus may also reduce the effectiveness of the antivirals.

Both antivirals have a five-year shelf life, say representatives for the drugs' manufacturers, Roche and GlaxoSmithKline.

Members help make our journalism possible. Become a Restaurant Business member today and unlock exclusive benefits, including unlimited access to all of our content. Sign up here.

Multimedia

Exclusive Content

Financing

Despite their complaints, customers keep flocking to Chipotle

The Bottom Line: The chain continued to be a juggernaut last quarter, with strong sales and traffic growth, despite frequent social media complaints about shrinkflation or other challenges.

Operations

Hitting resistance elsewhere, ghost kitchens and virtual concepts find a happy home in family dining

Reality Check: Old-guard chains are finding the alternative operations to be persistently effective side hustles.

Financing

The Tijuana Flats bankruptcy highlights the dangers of menu miscues

The Bottom Line: The fast-casual chain’s problems following new menu debuts in 2021 and 2022 show that adding new items isn’t always the right idea.

Trending

More from our partners